Trial reportJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2025
Effectiveness of Yiqi Chupi powder for alleviating cancer-related fatigue in patients following colorectal cancer surgery: a randomized controlled trial.
Trial report in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circadian Rhythms in Colorectal Cancer: Recent Advances in Development and Treatment.Journal of clinical medicine research · 2026Review
- Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of Yiqi Chupi powder (, YQCPP) in reducing cancer-related fatigue (CRF) among patients with colorectal cancer (CRC) undergoing chemotherapy.
methodsThis was a prospective, randomized controlled trial. Eligible patients were randomly assigned to either the experimental group, receiving a 12-week regimen of YQCPP and capecitabine plus oxaliplatin (XELOX) chemotherapy, or the control group, receiving a 12-week XELOX chemotherapy alone. Outcome measures were collected at baseline and subsequently at weeks 3, 6, 9, and 12 of the treatment period. The primary outcome was the Piper Fatigue Scale (PFS) score. The secondary outcomes were the Traditional Chinese Medicine syndrome and Karnofsky Performance Status (KPS) scores.
resultsOf 84 patients initially enrolled, 78 (92.9%) were evaluable. The experimental group exhibited significantly lower PFS scores (
conclusionYQCPP may decrease the CRF and improve quality of life in patients with CRC undergoing chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.